secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001104659-25-101688
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences raises 2025 revenue guidance after Q3 WAKIX revenue of $239M (+29% YoY)
--------------------------------------------------------------------------------

- Preliminary Q3 2025 WAKIX net revenue of ~$239M, up 29% year-over-year.
- Average patient count rose by ~500 to 8,100 in Q3, the largest quarterly increase ever.
- 2025 revenue guidance raised to $845-$865M from prior $820-$860M.
- Full Q3 2025 earnings and conference call scheduled for November 4, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/0001104659-25-101688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-101688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer